In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Statins may be associated with reduced mortality in four common cancers

High cholesterol diagnosis associated with lower risk of death in lung, breast, prostate and bowel cancers

Cardiovascular Pharmacotherapy


Embargoed 8 July 2016 at 17:00 CEST

Florence, Italy – 8 July 2016: A diagnosis of high cholesterol is associated with reduced mortality and improved survival in the four most common cancers, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016.1 The 14 year study from nearly one million patients found that a high cholesterol diagnosis was associated with lower risk of death in lung, breast, prostate and bowel cancers.

“The discovery of a link between obesity and high cholesterol as risk factors for cancer has been exciting for researchers and the public,” said lead author Dr Paul Carter from the ACALM Study Unit at Aston Medical School, Aston University in Birmingham, UK. “Even trendier is the idea that if high cholesterol can cause cancer, then cholesterol lowering interventions such as statins could reduce this risk.”

He continued: “We previously found an association between having high cholesterol and developing breast cancer.2 Animal studies show that giving statins for high cholesterol can reduce the risk of breast cancer. We wanted to see if there was any effect of high cholesterol on mortality amongst cancer patients.”

The current study investigated the association between high cholesterol and mortality in patients with lung, breast, prostate and bowel cancer, the four most common cancers in the UK. Patients admitted to UK hospitals with these cancers between 1 January 2000 and 31 March 2013 were recruited from the Algorithm for Comorbidities, Associations, Length of stay and Mortality (ACALM) clinical database, which also had information on co-existing conditions such as high cholesterol. Mortality data was obtained from the Office for National Statistics.

Out of a total of 929 552 patients in the ACALM study, 7997 had lung cancer, 5481 had breast cancer, 4629 had prostate cancer, and 4570 had bowel cancer.

After adjusting for factors which might influence mortality, including age, gender, ethnicity, and the ten most common causes of death in the UK, the researchers found that patients with cancer were less likely to die if they had a diagnosis of high cholesterol than if they did not. Having a diagnosis of high cholesterol was associated with a 22% lower risk of death in patients with lung cancer, 43% lower risk of death in breast cancer, 47% lower risk of death in prostate cancer, and 30% lower risk of death in bowel cancer.

Dr Carter said: “Our research suggests that there’s something about having a high cholesterol diagnosis that improves survival and the extent to which it did that was quite striking in the four cancers studied. Based on previous research we think there’s a very strong possibility that statins are producing this effect.”

He continued: “Because we saw the association amongst all four cancers we studied, we think this effect is caused by medications used for high cholesterol such as statins. These findings are likely to be seen in other cancers as well but this is only speculation and would need to be confirmed by studies in different types of cancer.”

Dr Rahul Potluri, senior author and founder of the ACALM Study Unit, said: "Statins have some of the best mortality evidence amongst all cardiovascular medications and statin use in patients with a diagnosis of high cholesterol is possibly the main reason that this diagnosis appears to be protective against death in patients with lung, breast, prostate and bowel cancer. Other cardiovascular medications may also be protective and explain the varying levels of risk reduction in the four cancer types. For example, prostate cancer is associated with heart disease and these patients tend to take ACE inhibitors and beta-blockers."

He added: “The results of this study strengthen the argument for a clinical trial evaluating the possible protective effect of statins and other routinely used cardiovascular medications such as aspirin, blood pressure medications, beta-blockers and ACE inhibitors in patients with cancer. Whether it is statins and/or other cardiovascular drugs in combination that have an effect on mortality remains to be seen.”

Dr Potluri concluded: “Patients with cancer who are at high risk or have established cardiovascular disease should be given statins as per current guidelines. I don’t think at the moment we can give statins for cancer per se. But this could change if there was a positive result in the clinical trial.”

ENDS

References

References and notes

1Dr Carter will present the abstract ‘Hyperlipidaemia reduces mortality in breast, prostate, lung and bowel cancer’ during the session Mechanisms of cancer-related cardiomyopathy which takes place on 8 July from 17:00 to 18:30 in the Sala Verde lecture room.

2Research presented at FCVB 2014

Notes to editor

Authors ESC Press Office
Tel: +33 (0)4 89 87 24 83
Email: press@escardio.org

 

SOURCES OF FUNDING: None.

 

DISCLOSURES: None.

 

About Frontiers in CardioVascular Biology

Frontiers in CardioVascular Biology (FCVB) is a comprehensive basic science conference organised every two years by the ESC Council on Basic Cardiovascular Science, whose mission is to enhance the importance of basic science to clinical cardiology. FCVB is organised in collaboration with 13 European cardiovascular science societies.


About the European Society of Cardiology

The European Society of Cardiology (ESC) represents more than 95 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

 

Information for journalists attending FCVB 2016

FCVB 2016 takes place 8 to 10 July in Florence, Italy at the Palazzo dei Congressi. The full scientific programme is available here

  • To register on-site please bring a valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related, or referring to a previous ESC Event).
  • Press registration is not available to industry or its public relations representatives, event management, marketing or communications representatives.